TRPA1 and migraine disorder: Additionally, preclinical data support the activation of TRPA1 in migraine mechanisms such as increased dural blood flow and neurogenic vasodilatation via the release of calcitonin gene-related peptide (CGRP), a neuropeptide for which monoclonal antibodies have been recently FDA-approved for the treatment of migraine (Tso and Goadsby, 2017).